WP3
Pr. Gabriel STEG
The WP3 Coordinator
Pr Steg is Chief (Department of Cardiology, Bichat Hospital, Paris, France); Vice President for research of the board of the Assistance Publique-Hôpitaux de Paris network; Professor of Cardiology at Université de Paris and Chair of the FACT (French Alliance for cardiovascular Clinical Trials) academic research network. Dr Steg has experience as a clinical trialist in coronary artery disease, diabetes and antithrombotics and has authored more than 1 000 peer-reviewed articles. His H-Index is 116 and he has more than 76 000 citations. He has been ”highly cited researcher” every year since 2014.
Pr. Emmanuelle VIDAL-PETIOT
The WP3 Coordinator
Pr Emmanuelle Vidal-Petiot (MD, PhD) is a European Hypertension specialist at Bichat University hospital (France) and Professor of Physiology at Paris University. Her scientific interests are mainly oriented on the mechanisms of blood pressure regulation, on renal physiology, and on the cardiovascular consequences of hypertension and chronic kidney disease. Pr Vidal-Petiot is involved in several clinical and translational research projects on hypertension within the FHU Apollo network, based on very large national or international cohorts.
WP3 Objectives
Atherosclerosis is a heterogeneous disease recognized as primary cause of death worldwide. Conventional risk factors remain under-controlled while a number of so far neglected risk factors are emerging. Immune and inflammatory process play a major role in atherosclerosis genesis and progression. We will use a population-based approach to evaluate immune and nonimmune factors in the general process of atherosclerosis disease. Progress is needed to fill the gap between early clinical development and pivotal trials, by defining validated surrogate markers for clinical outcomes, by developing registry-based randomized trials, and thereby by better targeting therapies.
WP3 Participants
Pr Jacques BLACHER
Diagnostic and therapeutic center - APHP Hotel-Dieu Hospital
Pr Catherine BOILEAU & Pr Guillaume JONDEAU & Dr Mathilde VARRET
INSERM U1148 Laboratory for Vascular Translational Science : Team 2 "Cardiovascular Structural Diseases" - University of Paris
Dr Marie-Christine BOUTON & Pr Nathalie KUBIS
INSERM U1148 Laboratory for Vascular Translational Science : Team 6 "Hemostasis, Thrombo-inflammation and Neurovascular Repair" - University of Paris
Dr Giuseppina CALIGIURI & Pr Antonino NICOLETTI
INSERM U1148 Laboratory for Vascular Translational Science : Team 1 "Cardiovascular Immunobiology" -University of Paris
Pr Yves CASTIER
Department of Thoracic and vascular surgery - APHP Bichat Hospital
Pr Eric DAUGAS
Nephrology Department - APHP Bichat Hospital
Dr Justine FRIJA-MASSON
Physiology department - APHP Bichat Hospital
Dr Didier LETOURNEUR
INSERM U1148 Laboratory For Vascular Translational Science : Team 3 "Cardiovascular Bioengineering" - University of Paris
Pr Marie-Pia d’ORTHO
Physiology department - APHP Bichat Hospital
Pr Benjamin SALMON
Oral and Dental medicine - APHP Bretonneau Hospital
Main achievements
One-Year Major Cardiovascular Events After Restrictive Versus Liberal Blood Transfusion Strategy in Patients With Acute Myocardial Infarction and Anemia: The REALITY Randomized Trial. Gonzalez-Juanatey JR, Lemesle G, Puymirat E, Ducrocq G, Cachanado M, Arnaiz JA, Martínez-Sellés M, Silvain J, Ariza-Solé A, Ferrari E, Calvo G, Danchin N, Avendano-Solá C, Rousseau A, Vicaut E, Gonzalez-Ferrero T, Steg PG, Simon T; REALITY Investigators. Circulation. 2022.
Intracranial Hemorrhage in the TST Trial. Amarenco P, Kim JS, Labreuche J, Charles H, Giroud M, Lavallée PC, Lee BC, Mahagne MH, Meseguer E, Nighoghossian N, Steg PG, Vicaut É, Bruckert E; Treat Stroke to Target Investigators*. Stroke. 2022.
Prevalence of diabetes and impact on cardiovascular events and mortality in patients with chronic coronary syndromes, across multiple geographical regions and ethnicities. Mak KH, Vidal-Petiot E, Young R, Sorbets E, Greenlaw N, Ford I, Tendera M, Ferrari R, Tardif JC, Udell JA, Escobedo J, Fox KM, Steg PG; CLARIFY Investigators. Eur J Prev Cardiol. 2022.
International Observational Analysis of Evolution and Outcomes of Chronic Stable Angina: The Multinational CLARIFY Study. Mesnier J, Ducrocq G, Danchin N, Ferrari R, Ford I, Tardif JC, Tendera M, Fox KM, Steg PG; CLARIFY Investigators. Circulation. 2021.
Sotagliflozin in Patients with Diabetes and Recent Worsening Heart Failure. Bhatt DL, Szarek M, Steg PG, Cannon CP, Leiter LA, McGuire DK, Lewis JB, Riddle MC, Voors AA, Metra M, Lund LH, Komajda M, Testani JM, Wilcox CS, Ponikowski P, Lopes RD, Verma S, Lapuerta P, Pitt B; SOLOIST-WHF Trial Investigators. N Engl J Med. 2021.
Sotagliflozin in Patients with Diabetes and Chronic Kidney Disease. Bhatt DL, Szarek M, Pitt B, Cannon CP, Leiter LA, McGuire DK, Lewis JB, Riddle MC, Inzucchi SE, Kosiborod MN, Cherney DZI, Dwyer JP, Scirica BM, Bailey CJ, Díaz R, Ray KK, Udell JA, Lopes RD, Lapuerta P, Steg PG; SCORED Investigators. N Engl J Med. 2021.
Prevalence of hypertensive disorders during pregnancy in France (2010-2018): The Nationwide CONCEPTION Study. Olié V, Moutengou E, Grave C, Deneux-Tharaux C, Regnault N, Kretz S, Gabet A, Mounier-Vehier C, Tsatsaris V, Plu-Bureau G, Blacher J. J Clin Hypertens (Greenwich). 2021.
Hyperventilation as one of the mechanisms of persistent dyspnoea in SARS-CoV-2 survivors. Motiejunaite J, Balagny P, Arnoult F, Mangin L, Bancal C, Vidal-Petiot E, Flamant M, Jondeau G, Cohen-Solal A, d'Ortho MP, Frija-Masson J. Eur Respir J. 2021.
Chronic use of renin-angiotensin-aldosterone system blockers and mortality in COVID-19: A multicenter prospective cohort and literature review. Gault N, Esposito-Farèse M, Revest M, Inamo J, Cabié A, Polard É, Hulot JS, Ghosn J, Chirouze C, Deconinck L, Diehl JL, Poissy J, Epaulard O, Lefèvre B, Piroth L, De Montmollin E, Oziol E, Etienne M, Laouénan C, Rossignol P, Costagliola D, Vidal-Petiot E; French-Covid cohort investigators, study group. Fundam Clin Pharmacol. 2021.
Association between renin-angiotensin-aldosterone system blockers and outcome in coronavirus disease 2019: analysing in-hospital exposure generates a biased seemingly protective effect of treatment. Lahens A, Mullaert J, Gressens S, Gault N, Flamant M, Deconinck L, Joly V, Yazdanpanah Y, Lescure FX, Vidal-Petiot E. J Hypertens. 2021.
Trajectory of extracellular fluid volume over time and subsequent risks of end-stage kidney disease and mortality in chronic kidney disease: a prospective cohort study. Faucon AL, Leffondré K, Flamant M, Metzger M, Boffa JJ, Haymann JP, Houillier P, Thervet E, Vrtovsnik F, Proust-Lima C, Stengel B, Vidal-Petiot E, Geri G; NephroTest study group. J Intern Med. 2021.
Task 4.2 : Genetic factors for hypercholesterolemia
Posttranscriptional Regulation of the Human LDL Receptor by the U2-Spliceosome. Zanoni P, Panteloglou G, Othman A, Haas JT, Meier R, Rimbert A, Futema M, Abou Khalil Y, Norrelykke SF, Rzepiela AJ, Stoma S, Stebler M, van Dijk F, Wijers M, Wolters JC, Dalila N, Huijkman NCA, Smit M, Gallo A, Carreau V, Philippi A, Rabès JP, Boileau C, Visentin M, Vonghia L, Weyler J, Francque S, Verrijken A, Verhaegen A, Van Gaal L, van der Graaf A, van Rosmalen BV, Robert J, Velagapudi S, Yalcinkaya M, Keel M, Radosavljevic S, Geier A, Tybjaerg-Hansen A, Varret M, Rohrer L, Humphries SE, Staels B, van de Sluis B, Kuivenhoven JA, von Eckardstein A. Circ Res. 2022.
APOE gene variants in primary dyslipidemia. Khalil YA, Rabès JP, Boileau C, Varret M. Atherosclerosis. 2021.
Identification of a Variant in APOB Gene as a Major Cause of Hypobetalipoproteinemia in Lebanese Families. Ayoub C, Azar Y, Abou-Khalil Y, Ghaleb Y, Elbitar S, Halaby G, Jambart S, Gannagé-Yared MH, Yaghi C, Saade Riachy C, El Khoury R, Rabès JP, Varret M, Boileau C, El Khoury P, Abifadel M .Metabolites. 2021.
Lipoprotein(a): Pathophysiology, measurement, indication and treatment in cardiovascular disease. A consensus statement from the Nouvelle Société Francophone d'Athérosclérose (NSFA). Durlach V, Bonnefont-Rousselot D, Boccara F, Varret M, Di-Filippo Charcosset M, Cariou B, Valero R, Charriere S, Farnier M, Morange PE, Meilhac O, Lambert G, Moulin P, Gillery P, Beliard-Lasserre S, Bruckert E, Carrié A, Ferrières J, Collet X, Chapman MJ, Anglés-Cano E. Arch Cardiovasc Dis. 2021.
Genetic Testing in Familial Hypercholesterolemia: Strengthening the Tools, Reinforcing Efforts, and Diagnosis. Abifadel MS, Rabès JH, Boileau C. JACC Basic Transl Sci. 2021.